Stock listing
NASDAQ:MIRA MIRA Pharmaceuticals, Inc. Stock
Home listing (NASDAQ) of MIRA Pharmaceuticals, Inc.
Follow MIRA Pharmaceuticals, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:MIRA
$0.291 USD -0.077 (-20.9%)
Close on Nov 20, 2026
- Day range
- $0.255 – $0.392 USDNov 20, 2026
- Volume
- 556,100 sharesNov 20, 2026
- Market cap
- $12.23M USDAt the close on Nov 20, 2026 · price × 42.02M shares outstanding
- 52-week range
- $0.255 – $1.690 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $489,843 USDMedian day 102,850 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:MIRA · Home | $0.291 USD | -0.077 (-20.9%) | 556,100 | $0.392 | $0.392 | $0.255 | $0.368 | Close on Nov 20, 2026 |
| Frankfurt:K6S | €0.527 EUR | -0.047 (-8.3%) | — | €0.526 | €0.527 | €0.526 | €0.574 | Close on Nov 19, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:MIRA · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.291 | -0.077 | -20.9% | $0.392 | $0.392 | $0.255 | 556,100 | |
| $0.368 | -0.223 | -37.7% | $0.590 | $0.590 | $0.331 | 589,600 | |
| $0.591 | -0.049 | -7.7% | $0.645 | $0.645 | $0.580 | 160,200 | |
| $0.640 | +0.009 | +1.4% | $0.640 | $0.661 | $0.620 | 164,100 | |
| $0.631 | -0.029 | -4.4% | $0.640 | $0.665 | $0.611 | 58,300 | |
| $0.660 | +0.012 | +1.9% | $0.638 | $0.664 | $0.611 | 90,900 | |
| $0.648 | +0.026 | +4.2% | $0.622 | $0.660 | $0.617 | 63,200 | |
| $0.622 | +0.001 | +0.2% | $0.620 | $0.632 | $0.603 | 52,500 | |
| $0.621 | +0.002 | +0.3% | $0.610 | $0.640 | $0.600 | 50,300 | |
| $0.619 | +0.048 | +8.4% | $0.560 | $0.630 | $0.550 | 236,900 | |
| $0.571 | +0.031 | +5.7% | $0.540 | $0.588 | $0.540 | 28,100 | |
| $0.540 | -0.021 | -3.7% | $0.568 | $0.575 | $0.520 | 115,000 | |
| $0.561 | +0.043 | +8.3% | $0.520 | $0.600 | $0.520 | 79,700 | |
| $0.518 | -0.019 | -3.5% | $0.530 | $0.550 | $0.510 | 83,100 | |
| $0.537 | -0.012 | -2.2% | $0.589 | $0.589 | $0.530 | 132,200 | |
| $0.549 | -0.023 | -4.0% | $0.589 | $0.589 | $0.510 | 207,900 | |
| $0.572 | +0.016 | +2.9% | $0.574 | $0.630 | $0.552 | 378,400 | |
| $0.556 | +0.006 | +1.1% | $0.550 | $0.578 | $0.540 | 722,800 | |
| $0.550 | +0.017 | +3.2% | $0.540 | $0.570 | $0.535 | 87,900 | |
| $0.533 | -0.087 | -14.0% | $0.647 | $0.647 | $0.518 | 252,700 | |
| $0.620 | -0.009 | -1.4% | $0.630 | $0.660 | $0.600 | 106,100 | |
| $0.629 | -0.053 | -7.8% | $0.730 | $0.730 | $0.622 | 100,200 | |
| $0.682 | +0.032 | +4.9% | $0.665 | $0.693 | $0.665 | 128,700 | |
| $0.650 | +0.008 | +1.2% | $0.645 | $0.661 | $0.645 | 10,500 | |
| $0.642 | +0.010 | +1.6% | $0.626 | $0.647 | $0.623 | 66,100 | |
| $0.632 | -0.026 | -4.0% | $0.680 | $0.680 | $0.631 | 123,200 | |
| $0.658 | -0.024 | -3.5% | $0.635 | $0.679 | $0.626 | 128,600 | |
| $0.682 | +0.016 | +2.4% | $0.667 | $0.686 | $0.660 | 75,900 | |
| $0.666 | -0.039 | -5.5% | $0.699 | $0.700 | $0.660 | 67,700 | |
| $0.705 | -0.041 | -5.5% | $0.759 | $0.759 | $0.685 | 90,000 | |
| $0.746 | +0.043 | +6.1% | $0.720 | $0.750 | $0.703 | 52,400 | |
| $0.703 | -0.007 | -1.0% | $0.710 | $0.710 | $0.681 | 142,500 | |
| $0.710 | -0.002 | -0.3% | $0.722 | $0.741 | $0.703 | 67,700 | |
| $0.712 | -0.024 | -3.3% | $0.759 | $0.760 | $0.700 | 105,700 | |
| $0.736 | +0.006 | +0.8% | $0.730 | $0.750 | $0.711 | 86,400 | |
| $0.730 | +0.007 | +1.0% | $0.730 | $0.758 | $0.711 | 158,000 | |
| $0.723 | -0.122 | -14.4% | $0.840 | $0.850 | $0.620 | 667,700 | |
| $0.845 | -0.027 | -3.1% | $0.859 | $0.869 | $0.820 | 72,100 | |
| $0.872 | -0.031 | -3.4% | $0.870 | $0.900 | $0.865 | 61,400 | |
| $0.903 | +0.003 | +0.3% | $0.898 | $0.911 | $0.875 | 65,800 | |
| $0.900 | +0.060 | +7.1% | $0.860 | $0.900 | $0.850 | 94,700 | |
| $0.840 | -0.018 | -2.1% | $0.858 | $0.860 | $0.831 | 54,100 | |
| $0.858 | -0.048 | -5.3% | $0.936 | $0.940 | $0.850 | 118,600 | |
| $0.906 | +0.027 | +3.1% | $0.865 | $0.919 | $0.847 | 127,800 | |
| $0.879 | +0.047 | +5.6% | $0.821 | $0.900 | $0.798 | 387,600 | |
| $0.832 | +0.073 | +9.6% | $0.789 | $0.832 | $0.770 | 682,600 | |
| $0.759 | +0.039 | +5.4% | $0.730 | $0.760 | $0.722 | 131,400 | |
| $0.720 | +0.006 | +0.8% | $0.720 | $0.737 | $0.710 | 76,500 | |
| $0.714 | -0.039 | -5.2% | $0.753 | $0.754 | $0.714 | 71,500 | |
| $0.753 | -0.021 | -2.7% | $0.766 | $0.780 | $0.728 | 171,500 | |
| $0.774 | -0.015 | -1.9% | $0.789 | $0.820 | $0.774 | 105,500 | |
| $0.789 | +0.008 | +1.0% | $0.790 | $0.830 | $0.759 | 138,400 | |
| $0.781 | +0.005 | +0.6% | $0.771 | $0.794 | $0.756 | 53,200 | |
| $0.776 | +0.012 | +1.6% | $0.760 | $0.810 | $0.751 | 177,200 | |
| $0.764 | +0.024 | +3.2% | $0.735 | $0.850 | $0.735 | 338,500 | |
| $0.740 | -0.110 | -12.9% | $0.830 | $0.840 | $0.731 | 490,500 | |
| $0.850 | -0.010 | -1.2% | $0.857 | $0.935 | $0.825 | 575,000 | |
| $0.860 | +0.090 | +11.7% | $0.740 | $1.100 | $0.721 | 29,281,100 | |
| $0.770 | +0.020 | +2.7% | $0.750 | $0.782 | $0.750 | 44,300 | |
| $0.750 | -0.020 | -2.6% | $0.750 | $0.779 | $0.750 | 31,800 | |
| $0.770 | +0.020 | +2.7% | $0.750 | $0.778 | $0.740 | 44,100 | |
| $0.750 | -0.025 | -3.2% | $0.770 | $0.774 | $0.750 | 27,300 | |
| $0.775 | -0.013 | -1.6% | $0.800 | $0.810 | $0.768 | 34,700 | |
| $0.788 | +0.024 | +3.1% | $0.779 | $0.825 | $0.770 | 65,100 | |
| $0.764 | +0.054 | +7.6% | $0.720 | $0.820 | $0.720 | 117,400 | |
| $0.710 | -0.060 | -7.8% | $0.770 | $0.796 | $0.710 | 41,700 |
- Ticker
- NASDAQ:MIRA
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 17, 2026
MIRA Pharmaceuticals Reports New MIRA-55 Selectivity Findings Supporting a Differentiated Non-Opioid Approach to Pain
Latest deck · October 2026
Investor Presentation (October 2026)
Investor deck · 30 slides
Latest news
MIRA Pharmaceuticals Reports New MIRA-55 Selectivity Findings Supporting a Differentiated Non-Opioid Approach to Pain
Nov 17, 2026
Closed $0.64 (+1.4%) on Nov 17, 2026
MIRA Pharmaceuticals Reports Significant Weight and Fat Reduction With Oral SKNY-1 in Obese Mice, Showing Favorable Lean-Mass and Weight-Regain Outcomes Compared With Semaglutide
Oct 29, 2026
Closed $0.572 (+2.9%) on Oct 29, 2026
MIRA Pharmaceuticals Reports MIRA-55 Demonstrated Significant Pain Relief Comparable to Celebrex in Chronic Inflammatory Pain Study
Oct 22, 2026
Closed $0.629 (-7.8%) on Oct 22, 2026
MIRA Pharmaceuticals Advances Ketamir-2 to Phase 2a in Chemotherapy-Induced Peripheral Neuropathy (CIPN) Following FDA Review
Sep 17, 2026
Closed $0.759 (+5.4%) on Sep 17, 2026
MIRA Pharmaceuticals Advances Non-Opioid Oral MIRA-55 for Inflammatory Pain Toward IND
Sep 1, 2026
Closed $0.86 (+11.7%) on Sep 1, 2026
MIRA Reports Positive 7-Day Dog Study Results for SKNY-1
Aug 6, 2026
Closed $0.678 (+3.0%) on Aug 6, 2026
MIRA Pharmaceuticals Progresses MIRA-55 and SKNY-1 Toward IND-Enabling Studies
Jul 30, 2026
Closed $0.816 (-3.1%) on Jul 30, 2026
MIRA Pharmaceuticals Reports Successful Formulation Results Supporting Development of MIRA-55 as a Non-Opioid Oral Therapy for Chronic Inflammatory Pain
Jul 10, 2026
Closed $0.925 (+0.5%) on Jul 10, 2026
MIRA Pharmaceuticals Reports Successful Formulation Results for SKNY-1, Its Oral Drug Candidate for Obesity and Addiction
Jul 6, 2026
Closed $0.955 (+1.1%) on Jul 6, 2026
MIRA Pharmaceuticals, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 19 in the last 12 months · 79 in all · newest Nov 17, 2026 · oldest 2023
- Decks
- 3 decks · latest October 2026
Where MIRA Pharmaceuticals, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:MIRA · Home listing · This page | NASDAQ | United States | USD |
| gettex:K6S | gettex | Germany | EUR |
| Lang & Schwarz:A3EQWL | Lang & Schwarz | Germany | EUR |
| LS Exchange:A3EQWL | LS Exchange | Germany | EUR |
| BOATS:MIRA | BOATS | United States | USD |
| Tradegate:K6S | Tradegate | Germany | EUR |
| Dusseldorf:K6S | Dusseldorf | Germany | EUR |
| Frankfurt:K6S | Frankfurt | Germany | EUR |
| Hamburg:K6S | Hamburg | Germany | EUR |
| Munich:K6S | Munich | Germany | EUR |
| Stuttgart:K6S | Stuttgart | Germany | EUR |
Valuation
Price/book 1.8× against a median of 11.9×: 3rd lowest of 7 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $5.26M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- No depreciation figure on 6ix yet
- Price/book
- 1.8×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 1.48
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| MIRA Pharmaceuticals, Inc. · NASDAQ:MIRA | US$12.23M | US$5.26M | n/a | n/a | n/a | 1.8× | n/a | 0.0× | 1.48 |
| Seres Therapeutics, Inc. · NASDAQ:MCRB | US$12.64M | US$30.89M | n/a | 14.5× | n/a | 0.6× | n/a | 1.7× | 1.21 |
| Passage Bio, Inc. · NASDAQ:PASG | US$12.61M | −US$7.55M | n/a | n/a | n/a | 252× | n/a | 0.0× | 1.94 |
| Allarity Therapeutics, Inc. · NASDAQ:ALLR | US$12.56M | US$21.48M | n/a | 61.4× | n/a | n/a | n/a | n/a | 1.40 |
| Lobe Sciences Ltd · CSE:LOBE | US$12.52M | US$8.89M | n/a | n/a | n/a | 9.5× | n/a | 0.0× | 0.31 |
| Biophytis SA · EURONEXT:ALBPS | US$12.47M | US$19.44M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Genflow Biosciences PLC · LSE:GENF | US$12.06M | US$11.23M | n/a | n/a | n/a | 48.5× | n/a | 0.0× | n/a |
| BioCardia, Inc. · NASDAQ:BCDA | US$11.88M | US$10.22M | n/a | n/a | n/a | 14.2× | n/a | 0.7× | 0.42 |
| Xintela AB · OMXSTO:XINT | US$11.88M | US$11.81M | n/a | 39.8× | n/a | n/a | n/a | n/a | n/a |
| Pluri Inc. · NASDAQ:PLUR | US$11.85M | US$38.65M | n/a | 26.5× | n/a | n/a | n/a | n/a | 0.53 |
| Synlogic Inc · OTC:SYBX | US$11.76M | US$201,442 | n/a | n/a | n/a | 1.2× | n/a | 0.0× | 0.50 |
| Median of the others | US$12.26M | US$11.52M | 33.2× | 11.9× | 0.0× | 0.53 |
Forecasts
1 buy · Analysts' consensus from EODHD, read Nov 21, 2026. Not 6ix's view and not investment advice.
- Price target
- 3.50 USD · Analysts' mean
- EPS, year to Dec 2026
- -0.12 · 1 analyst
Team and board
Officers
| Officer | Role |
|---|---|
| Erez Aminov | Chairman of the Board and Chief Executive Officer |
| Andriy Mushak | Chief Financial Officer |
| Itzchak Angel | Chief Scientific Advisor |
Board
| Director | Role |
|---|---|
| Erez Aminov | Chairman of the Board and Chief Executive Officer |
| Denil N. Shekhat | Director |
| Matthew Del Giudice | Director |
| Matthew Pratt Whalen | Director |
| Ned MacPherson | Director |
Events
- Next results
- Nov 26, 2026 (expected)
| Quarter | Results | Share move |
|---|---|---|
| Q2 2026 | Aug 12, 2026 | −3.6% |
| Q1 2026 | Jun 3, 2026 | +1.9% |
| Q4 2025 | Feb 25, 2026 | +6.4% |
| Q3 2025 | Nov 13, 2025 · Before open | −6.3% |
| Q2 2025 | Aug 14, 2025 · After close | +2.0% |
| Q1 2025 | May 14, 2025 · After close | +6.8% |
| Q4 2024 | Feb 26, 2025 | 0.0% |
| Q3 2024 | Nov 12, 2024 · After close | −2.5% |
| Q2 2024 | Aug 13, 2024 · After close | −5.8% |
| Q1 2024 | May 13, 2024 · After close | +3.0% |
All 13 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q4 2023 | Feb 28, 2024 | −4.3% |
| Q3 2023 | Nov 13, 2023 · After close | +11.7% |
| Q2 2023 | Aug 30, 2023 | −1.7% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (October 2026) | Investor deck | 30 slides | October 2026 |
| Investor Presentation (April 2026) | Investor deck | 56 slides | April 2026 |
| Investor Presentation (June 2025) | Investor deck | 36 slides | June 2025 |
IPO
Priced at US$7.00 a share on Aug 2, 2023.
- Price
- US$7.00 a share
- Shares offered
- 1,275,000 shares of common stock
- Offering size
- US$8.9 million
- Underwriters' option
- Up to 191,250 more shares
- Listing
- MIRA on the Nasdaq Capital Market
- Underwriter
- Kingswood Investments
- Shares delivered
- On or about Aug 7, 2023
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Jun 29, 2022 |
| Filed publicly | Jun 29, 2023 |
| Amended 5 times | Newest Jul 28, 2023 |
| Shares registered with an exchange | Jul 31, 2023 |
| Declared effective by the SEC | Aug 2, 2023 |
| Final prospectus, with the price | Aug 4, 2023 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Aug 4, 2023 |
| 424B1 · Prospectus | Aug 4, 2023 |
| EFFECT · Notice that a registration is effective | Aug 2, 2023 |
| CERT · Exchange's certificate of listing | Jul 31, 2023 |
| CORRESP · Letter to the SEC | Jul 31, 2023 |
| CORRESP · Letter to the SEC | Jul 31, 2023 |
| 8-A12B · Registration of shares for listing on an exchange | Jul 31, 2023 |
| S-1/A · Registration statement, amended | Jul 28, 2023 |
| S-1/A · Registration statement, amended | Jul 25, 2023 |
| S-1/A · Registration statement, amended | Jul 21, 2023 |
All 23 filings
| Filing | Filed |
|---|---|
| S-1/A · Registration statement, amended | Jul 18, 2023 |
| CORRESP · Letter to the SEC | Jul 14, 2023 |
| S-1/A · Registration statement, amended | Jul 14, 2023 |
| CORRESP · Letter to the SEC | Jul 13, 2023 |
| UPLOAD · Letter from the SEC | Jul 10, 2023 |
| CORRESP · Letter to the SEC | Jun 29, 2023 |
| S-1 · Registration statement | Jun 29, 2023 |
| UPLOAD · Letter from the SEC | Jun 15, 2023 |
| DRSLTR · Letter to the SEC with a draft | Jun 8, 2023 |
| DRS/A · Draft registration statement, amended | Jun 8, 2023 |
| UPLOAD · Letter from the SEC | May 30, 2023 |
| DRS/A · Draft registration statement, amended | May 2, 2023 |
| DRS · Draft registration statement | Jun 29, 2022 |
Open IPO · From the cover of the final prospectus (424B1) filed Aug 4, 2023
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | |
| Cost of revenue | 8.53M | |||||
| Gross profit | -8.53M | |||||
| Research and development | 1.72M | 3.31M | 1.57M | 2.35M | 684.4K | 14.6K |
| Selling, general and administrative | 8.77M | 4.71M | 6.50M | 2.99M | 770.1K | 158.9K |
| Operating income | -10.5M | -8.02M | -8.53M | -7.05M | -2.15M | -67.6K |
| Depreciation and amortization | 2 | 732.3K | 7.05M | 2.15M | 202.9K | |
| EBITDA | -8.02M | -7.79M | 0 | 0 | 135.3K | |
| Interest expense | -165.7K | 3.46M | 10.3K | 24.4K | 364 | |
| Income before tax | -10.4M | -7.85M | -12.0M | -7.06M | -2.18M | -68.0K |
| Income tax | -8.53K | -7.05K | -2.15K | -203 | ||
| Net income | -10.4M | -7.85M | -12.0M | -7.06M | -2.18M | -68.0K |
| Earnings per share, basic | -1.35 | -0.51 | -0.85 | -0.40 | -0.15 | -0.00 |
| Earnings per share, diluted | -1.35 | -0.51 | -0.85 | -0.40 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Cash and equivalents | 6.35M | 2.83M | 4.60M | 351.0K | 2.81M | 3.49K |
| Short-term investments | 4.68M | 0 | ||||
| Receivables | 11.9K | |||||
| Inventory | -11.9K | |||||
| Current assets | 11.1M | 2.89M | 4.86M | 494.4K | 2.91M | 3.49K |
| Property, plant and equipment | 363.7K | |||||
| Total assets | 11.1M | 2.92M | 4.93M | 858.1K | 3.36M | 22.4K |
| Accounts payable | 129.2K | 723.3K | 538.6K | 905.6K | 228.4K | |
| Current liabilities | 702.1K | 723.3K | 558.1K | 1.37M | 1.09M | 90.4K |
| Total debt | 5.06K | 491.2K | 293.1K | 90.0K | ||
| Total liabilities | 702.1K | 723.3K | 558.1K | 1.45M | 1.09M | 90.4K |
| Shareholders' equity | 10.4M | 2.20M | 4.37M | -596.2K | 2.26M | -68.0K |
| Shares outstanding | 41.9M | 16.6M | 14.8M | 13.3M | 14.7M | 14.7M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Cash from operations | -4.66M | -5.56M | -4.53M | -5.60M | -1.38M | -68.0K |
| Capital spending | 0 | -4 | -1 | 0 | 0 | -3 |
| Free cash flow | -4.66M | -5.56M | -4.53M | -5.60M | -1.38M | -68.0K |
| Cash from financing | 8.18M | 3.79M | 8.78M | 3.15M | 4.18M | 71.1K |
| Change in cash | 3.51M | -1.77M | 4.25M | -2.46M | 2.81M | 3.49K |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 10-Q · Quarterly report | Nov 16, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 16, 2026 | Current report | SEC |
| 8-K · Current report | Oct 28, 2026 | Current report | SEC |
| 8-K · Current report | Oct 22, 2026 | Current report | SEC |
| 8-K · Current report | Sep 17, 2026 | Current report | SEC |
| 8-K · Current report | Sep 16, 2026 | Meeting outcome | SEC |
| 8-K · Current report | Sep 1, 2026 | Current report | SEC |
| 10-Q · Quarterly report | Aug 12, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 6, 2026 | Current report | SEC |
| 8-K · Current report | Jul 31, 2026 | Current report | SEC |
All 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| DEF 14A · Proxy statement | Jul 28, 2026 | Meeting notice | SEC |
| 8-K · Current report | Jul 10, 2026 | Current report | SEC |
| 8-K · Current report | Jul 6, 2026 | Current report | SEC |
| 8-K · Current report | Jun 25, 2026 | Current report | SEC |
| 8-K · Current report | Jun 17, 2026 | Current report | SEC |
| 4 · Change in ownership | Jun 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 15, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 9, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 8, 2026 | Management or board change | SEC |
| 8-K · Current report | Jun 4, 2026 | Material contract | SEC |
| 8-K · Current report | May 27, 2026 | Material contract | SEC |
| 10-Q · Quarterly report | May 14, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 13, 2026 | Current report | SEC |
| 8-K · Current report | May 13, 2026 | Current report | SEC |
| 4 · Change in ownership | Apr 1, 2026 | Insider trade | SEC |
| 10-K · Annual report | Mar 31, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 23, 2026 | Current report | SEC |
| 8-K · Current report | Mar 3, 2026 | Current report | SEC |
| 5 · Annual statement of ownership | Feb 17, 2026 | Insider trade | SEC |
| 8-K · Current report | Feb 2, 2026 | Current report | SEC |
| 8-K · Current report | Dec 19, 2025 | Management or board change | SEC |
| 8-K · Current report | Dec 5, 2025 | Current report | SEC |
| 424B5 · Prospectus | Dec 5, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | Nov 13, 2025 | Quarterly report | SEC |
| 8-K · Current report | Oct 23, 2025 | Current report | SEC |
| 8-K · Current report | Oct 16, 2025 | Current report | SEC |
| 8-K · Current report | Oct 15, 2025 | Current report | SEC |
| 4 · Change in ownership | Oct 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 3, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 3, 2025 | Insider trade | SEC |
| 8-K · Current report | Sep 30, 2025 | Acquisition or disposal | SEC |
| 8-K · Current report | Sep 22, 2025 | Current report | SEC |
| 4 · Change in ownership | Sep 18, 2025 | Insider trade | SEC |
| 8-K · Current report | Sep 15, 2025 | Current report | SEC |
| 8-K · Current report | Sep 11, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Sep 3, 2025 | Insider trade | SEC |
| 8-K · Current report | Aug 19, 2025 | Current report | SEC |
| 10-Q · Quarterly report | Aug 14, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 12, 2025 | Current report | SEC |
| DEFM14A | Aug 8, 2025 | Meeting notice | SEC |
| DEFA14A · Additional proxy material | Aug 8, 2025 | Meeting notice | SEC |
| PRER14A | Jul 29, 2025 | Other filings | SEC |
| 8-K · Current report | Jul 29, 2025 | Current report | SEC |
| 8-K · Current report | Jul 28, 2025 | Current report | SEC |
| 8-K · Current report | Jul 10, 2025 | Current report | SEC |
| 8-K · Current report | Jul 8, 2025 | Current report | SEC |
| 8-K · Current report | Jul 2, 2025 | Current report | SEC |
| 8-K · Current report | Jun 30, 2025 | Current report | SEC |
| 8-K · Current report | Jun 24, 2025 | Current report | SEC |
| 8-K · Current report | Jun 17, 2025 | Current report | SEC |
| PREM14A | Jun 17, 2025 | Other filings | SEC |
| 3 · Initial statement of ownership | Jun 10, 2025 | Insider trade | SEC |
| 8-K · Current report | May 28, 2025 | Current report | SEC |
| 8-K · Current report | May 21, 2025 | Material contract | SEC |
| 10-Q · Quarterly report | May 14, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 8, 2025 | Current report | SEC |
| 8-K · Current report | May 6, 2025 | Current report | SEC |
| 8-K · Current report | Apr 23, 2025 | Current report | SEC |
| 10-K/A · Annual report, amended | Apr 17, 2025 | Annual report | SEC |
| 424B5 · Prospectus | Apr 16, 2025 | Offer document | SEC |
| 8-K · Current report | Apr 16, 2025 | Current report | SEC |
| 10-K/A · Annual report, amended | Apr 15, 2025 | Annual report | SEC |
| 8-K · Current report | Apr 11, 2025 | Current report | SEC |
| 8-K · Current report | Apr 1, 2025 | Current report | SEC |
| 10-K · Annual report | Mar 28, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 24, 2025 | Material contract | SEC |
| 8-K · Current report | Mar 13, 2025 | Current report | SEC |
| 8-K · Current report | Mar 4, 2025 | Current report | SEC |
| 8-K · Current report | Dec 20, 2024 | Current report | SEC |
| 8-K · Current report | Dec 19, 2024 | Current report | SEC |
| 4 · Change in ownership | Dec 10, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 10, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 10, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 10, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 10, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 10, 2024 | Insider trade | SEC |
| 8-K · Current report | Dec 10, 2024 | Current report | SEC |
| 4 · Change in ownership | Nov 27, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Nov 26, 2024 | Insider trade | SEC |
| 8-K · Current report | Nov 21, 2024 | Management or board change | SEC |
| 144 · Notice of proposed sale | Nov 19, 2024 | Other filings | SEC |
| 8-K · Current report | Nov 19, 2024 | Current report | SEC |
| 10-Q · Quarterly report | Nov 12, 2024 | Quarterly report | SEC |
| 8-K · Current report | Oct 25, 2024 | Current report | SEC |
| 8-K · Current report | Oct 21, 2024 | Current report | SEC |
| 424B5 · Prospectus | Sep 27, 2024 | Offer document | SEC |
| S-8 · Registration statement for employee plans | Sep 27, 2024 | Offer document | SEC |
| 8-K · Current report | Sep 12, 2024 | Meeting outcome | SEC |
| 8-K · Current report | Sep 10, 2024 | Current report | SEC |
| 144/A · Notice of proposed sale, amended | Sep 6, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 4, 2024 | Other filings | SEC |
| 4 · Change in ownership | Aug 30, 2024 | Insider trade | SEC |
| 8-K · Current report | Aug 23, 2024 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Aug 19, 2024 | Other filings | SEC |
| 10-Q/A · Quarterly report, amended | Aug 16, 2024 | Quarterly report | SEC |
| CORRESP · Letter to the SEC | Aug 15, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Aug 15, 2024 | Other filings | SEC |
| 10-Q · Quarterly report | Aug 13, 2024 | Quarterly report | SEC |
| S-3 · Registration statement | Aug 12, 2024 | Offer document | SEC |
| 8-K · Current report | Aug 9, 2024 | Current report | SEC |
| 8-K · Current report | Aug 8, 2024 | Current report | SEC |
| DEFA14A · Additional proxy material | Jul 26, 2024 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Jul 26, 2024 | Meeting notice | SEC |
| 8-K · Current report | Jul 24, 2024 | Current report | SEC |
| 8-K · Current report | Jul 19, 2024 | Current report | SEC |
| 8-K · Current report | Jul 12, 2024 | Current report | SEC |
| 8-K · Current report | Jun 28, 2024 | Management or board change | SEC |
| 4 · Change in ownership | Jun 21, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 30, 2024 | Insider trade | SEC |
| 8-K · Current report | May 29, 2024 | Management or board change | SEC |
| 4 · Change in ownership | May 22, 2024 | Insider trade | SEC |
| 10-Q · Quarterly report | May 13, 2024 | Quarterly report | SEC |
| 10-K · Annual report | Apr 1, 2024 | Annual report | SEC |
| 4 · Change in ownership | Mar 27, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 27, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 27, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 27, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 27, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 27, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Mar 22, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Mar 22, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Mar 22, 2024 | Insider trade | SEC |
| 8-K · Current report | Mar 13, 2024 | Management or board change | SEC |
| 8-K · Current report | Mar 7, 2024 | Current report | SEC |
| 8-K · Current report | Jan 17, 2024 | Management or board change | SEC |
| EFFECT · Notice that a registration is effective | Dec 28, 2023 | Other filings | SEC |
| 4 · Change in ownership | Dec 27, 2023 | Insider trade | SEC |
| SC 13D/A · Big-stake notice, amended | Dec 27, 2023 | Big-stake notice | SEC |
| CORRESP · Letter to the SEC | Dec 22, 2023 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Dec 22, 2023 | Other filings | SEC |
| S-1 · Registration statement | Dec 18, 2023 | Offer document | SEC |
| 8-K · Current report | Dec 1, 2023 | Management or board change | SEC |
| SC 13D/A · Big-stake notice, amended | Nov 20, 2023 | Big-stake notice | SEC |
| 3 · Initial statement of ownership | Nov 20, 2023 | Insider trade | SEC |
| 8-K · Current report | Nov 20, 2023 | Material contract | SEC |
| 4 · Change in ownership | Nov 17, 2023 | Insider trade | SEC |
| 424B3 · Prospectus | Nov 13, 2023 | Offer document | SEC |
| 10-Q · Quarterly report | Nov 13, 2023 | Quarterly report | SEC |
| 3 · Initial statement of ownership | Nov 3, 2023 | Insider trade | SEC |
| 8-K · Current report | Oct 25, 2023 | Management or board change | SEC |
| 3 · Initial statement of ownership | Oct 12, 2023 | Insider trade | SEC |
| SC 13D/A · Big-stake notice, amended | Oct 12, 2023 | Big-stake notice | SEC |
| 424B3 · Prospectus | Sep 18, 2023 | Offer document | SEC |
| 10-Q · Quarterly report | Sep 15, 2023 | Quarterly report | SEC |
| 8-K · Current report | Aug 31, 2023 | Management or board change | SEC |
| 4 · Change in ownership | Aug 24, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Aug 21, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Aug 21, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Aug 21, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Aug 21, 2023 | Insider trade | SEC |
| SC 13D · Big-stake notice | Aug 14, 2023 | Big-stake notice | SEC |
| 8-K · Current report | Aug 7, 2023 | Material contract | SEC |
| 4 · Change in ownership | Aug 4, 2023 | Insider trade | SEC |
| 424B4 · Prospectus | Aug 4, 2023 | Offer document | SEC |
| 424B1 · Prospectus | Aug 4, 2023 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Aug 3, 2023 | Other filings | SEC |
| 3 · Initial statement of ownership | Aug 2, 2023 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 2, 2023 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 2, 2023 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 2, 2023 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 2, 2023 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 2, 2023 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 2, 2023 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 2, 2023 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 2, 2023 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 2, 2023 | Insider trade | SEC |
| CERT · Exchange's certificate of listing | Jul 31, 2023 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jul 31, 2023 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jul 31, 2023 | Other filings | SEC |
| 8-A12B · Registration of shares for listing on an exchange | Jul 31, 2023 | Other filings | SEC |
| S-1/A · Registration statement, amended | Jul 28, 2023 | Offer document | SEC |
| S-1/A · Registration statement, amended | Jul 25, 2023 | Offer document | SEC |
| S-1/A · Registration statement, amended | Jul 21, 2023 | Offer document | SEC |
| S-1/A · Registration statement, amended | Jul 18, 2023 | Offer document | SEC |
| CORRESP · Letter to the SEC | Jul 14, 2023 | Other filings | SEC |
| S-1/A · Registration statement, amended | Jul 14, 2023 | Offer document | SEC |
| CORRESP · Letter to the SEC | Jul 13, 2023 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jul 10, 2023 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jun 29, 2023 | Other filings | SEC |
| S-1 · Registration statement | Jun 29, 2023 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Jun 15, 2023 | Other filings | SEC |
| DRSLTR · Letter to the SEC with a draft | Jun 8, 2023 | Other filings | SEC |
| DRS/A · Draft registration statement, amended | Jun 8, 2023 | Offer document | SEC |
| UPLOAD · Letter from the SEC | May 30, 2023 | Other filings | SEC |
| DRS/A · Draft registration statement, amended | May 2, 2023 | Offer document | SEC |
| D | Aug 1, 2022 | Other filings | SEC |
| D | Aug 1, 2022 | Other filings | SEC |
| DRS · Draft registration statement | Jun 29, 2022 | Offer document | SEC |
Cap table
Built by 6ix from MIRA Pharmaceuticals, Inc.’s releases · as of Nov 13, 2026
- Common shares
- 42,022,087
- Fully diluted
- 42,022,087
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 42,022,087 | Nov 13, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 13, 2026 | 42,022,087 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Christopher C Chapman Jr Other companies: Telomir Pharmaceuticals, Inc. (CEO & Chairman, Director · Feb 8, 2024 – Feb 8, 2024 · Past); Q/C Technologies, Inc. (President, Chief Med. Officer, Director · Apr 16, 2021 – Jun 7, 2023 · Past); Rock Creek Pharmaceuticals Inc (President, Director · Sep 22, 2006 – Dec 27, 2013 · Past) | Executive Chairman, Director · Aug 2, 2023 – Aug 17, 2023 · Past |
| Michael Jerman Other companies: Alaunos Therapeutics, Inc. (Managing Partner of Hollywell Partners · Since at least Jul 15, 2025); Inhibitor Therapeutics Inc. (Director · Since at least Apr 1, 2024); Telomir Pharmaceuticals, Inc. (Director · Feb 8, 2024 – Aug 27, 2024 · Past) | Director · Nov 14, 2023 – Mar 25, 2024 · Past |
| Alan Weichselbaum Other companies: FinWise Bancorp (Director · Since at least May 27, 2025); Telomir Pharmaceuticals, Inc. (Chief Financial Officer · May 15, 2025 – May 15, 2025 · Past) | Chief Financial Officer · May 15, 2025 – May 15, 2025 · Past |
| Hugh McColl III Other companies: Westrock Coffee Company (Director · Since at least Aug 26, 2022); Telomir Pharmaceuticals, Inc. (Director · Feb 8, 2024 – Feb 8, 2024 · Past) | Director · Aug 2, 2023 – Aug 2, 2023 · Past |
| Michelle Yanez Other companies: Inhibitor Therapeutics Inc. (Director · Since at least Dec 13, 2022); Telomir Pharmaceuticals, Inc. (Chief Financial Officer · Jun 18, 2024 – Aug 27, 2024 · Past) | Chief Financial Officer · Aug 2, 2023 – Dec 9, 2024 · Past |
| Andriy Mushak Other companies: Telomir Pharmaceuticals, Inc. (Chief Financial Officer · Since at least Jun 3, 2026) | Chief Financial Officer · Since at least Jun 2, 2026 |
| Bradley Kroenig Other companies: Telomir Pharmaceuticals, Inc. (Director · Feb 8, 2024 – Feb 8, 2024 · Past) | Director · Aug 2, 2023 – Aug 2, 2023 · Past |
| Brian Frederick Daly Other companies: RRE Ventures Acquisition Corp. (Director · Since at least Mar 25, 2026) | Director · Oct 25, 2023 – Oct 25, 2023 · Past |
| David C Vorhoff Other companies: Sonic Automotive, Inc. (Director · Apr 19, 2012 – Apr 18, 2013 · Past) | Director · Aug 2, 2023 – Aug 2, 2023 · Past |
| Edward Clouston MacPherson Other companies: Telomir Pharmaceuticals, Inc. (Director · Since at least Aug 8, 2024) | Director · Since at least Mar 13, 2024 |
All 17 people
| Person | Seat |
|---|---|
| Erez Aminov Other companies: Telomir Pharmaceuticals, Inc. (Chairman and Chief Executive Officer · Since at least May 28, 2025) | Chief Executive Officer, Director · Since at least Aug 29, 2025 |
| Matthew Del Giudice Other companies: Telomir Pharmaceuticals, Inc. (Director · Since at least Nov 4, 2026) | Director · Since at least Nov 4, 2026 |
| Matthew Pratt Whalen Other companies: Telomir Pharmaceuticals, Inc. (Director · Since at least Aug 8, 2024) | Director · Since at least Nov 18, 2024 |
| Ned MacPherson Other companies: Telomir Pharmaceuticals, Inc. (Director · Since at least Nov 4, 2026) | Director · Since at least Nov 4, 2026 |
| Talhia Tuck Other companies: Telomir Pharmaceuticals, Inc. (Director · Feb 8, 2024 – Feb 8, 2024 · Past) | Director · Aug 2, 2023 – Aug 2, 2023 · Past |
| Denil N. Shekhat | Director · Since at least Oct 1, 2025 |
| Itzchak Angel | Chief Scientific Advisor · Since at least Oct 29, 2026 |
Log in to ask 6ix AI your own questions about MIRA Pharmaceuticals, Inc.